Bridgeway Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-17,896
Closed -$226K 1495
2018
Q3
$226K Sell
17,896
-15,000
-46% -$181K ﹤0.01% 1301
2018
Q2
$433K Sell
32,896
-17,350
-35% -$207K ﹤0.01% 1174
2018
Q1
$683K Sell
50,246
-2,150
-4% -$22.2K 0.01% 984
2017
Q4
$312K Sell
52,396
-650
-1% -$4.46K ﹤0.01% 1208
2017
Q3
$394K Buy
53,046
+650
+1% +$5.4K ﹤0.01% 1151
2017
Q2
$490K Sell
52,396
-25,000
-32% -$184K 0.01% 1094
2017
Q1
$563K Hold
77,396
0.01% 1037
2016
Q4
$573K Sell
77,396
-50,000
-39% -$360K 0.01% 1041
2016
Q3
$769K Buy
127,396
+68,900
+118% +$326K 0.01% 908
2016
Q2
$263K Buy
58,496
+8,496
+17% +$31.9K ﹤0.01% 1246
2016
Q1
$125K Hold
50,000
﹤0.01% 1355
2015
Q4
$405K Hold
50,000
0.01% 1125
2015
Q3
$303K Hold
50,000
0.01% 1213
2015
Q2
$412K Hold
50,000
0.01% 1159
2015
Q1
$378K Sell
50,000
-70,000
-58% -$547K 0.01% 1196
2014
Q4
$820K Hold
120,000
0.02% 852
2014
Q3
$540K Hold
120,000
0.01% 1033
2014
Q2
$702K Hold
120,000
0.02% 930
2014
Q1
$796K Buy
+120,000
New +$834K 0.02% 864

Other funds holding CCXI

Bridgeway Capital Management's CCXI Position: Q4 2018 in Review

Bridgeway Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2018, closing a stake of 17,896 shares — an estimated $226K sold.

Bridgeway Capital Management first reported a position in CCXI in Q1 2014 and held it in 19 quarters. The position peaked at $820K in Q4 2014. 108 funds tracked by Wall St. Rank hold CCXI as of Q4 2018.

  • Bridgeway Capital Management reported no remaining ChemoCentryx, Inc. position as of Q4 2018 after selling out during the quarter.
  • Bridgeway Capital Management sold 17,896 ChemoCentryx, Inc. shares in Q4 2018, an estimated $226K.
  • Bridgeway Capital Management first reported a position in ChemoCentryx, Inc. in Q1 2014 and held it in 19 quarters.
  • Bridgeway Capital Management's ChemoCentryx, Inc. position peaked at $820K in Q4 2014.
  • 108 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2018.

Based on Bridgeway Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.